Clopidogrel and heart failure survival: missed opportunity or wrong turn?

c H p a a m C c s o i d c o P t h t 0 s n o s o t m e p p p t a r i t a v w i t espite significant progress in the prevention and treatment f cardiovascular diseases over the past 2 decades, the ncidence, prevalence, morbidity, mortality, and economic mpact associated with heart failure (HF) represent a major nd growing public health concern (1,2). Thrombotic oclusions and thromboembolism are critical, but relatively ncommon life-threatening complications of HF. The exstence of HF per se increases the risk of thromboembolic vents, regardless of whether concomitant atrial fibrillation s present (3,4). Clopidogrel is a second-generation thienpyridine, an adenosine diphosphate receptor antagonist cting via platelet P2Y12 receptor blockade, and an estabished antiplatelet agent. Clopidogrel either as an alternative 5), or more commonly as an adjunct (6), to aspirin epresents a cornerstone of modern chronic oral antiplatelet